Daniel Gröner
About
In The Last Decade
Daniel Gröner
18 papers receiving 300 citations
Peers
Comparison fields: 5 of 55
- Endocrinology, Diabetes and Metabolism 214
- Surgery 195
- Epidemiology 39
- Radiology, Nuclear Medicine and Imaging 37
- Oncology 31
Countries citing papers authored by Daniel Gröner
This map shows the geographic impact of Daniel Gröner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Gröner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Gröner more than expected).
Fields of papers citing papers by Daniel Gröner
This network shows the impact of papers produced by Daniel Gröner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Gröner. The network helps show where Daniel Gröner may publish in the future.
Co-authorship network of co-authors of Daniel Gröner
This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Gröner. A scholar is included among the top collaborators of Daniel Gröner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Gröner. Daniel Gröner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 1 | |
| 4 | 3 | |
| 5 | 1 | |
| 6 | 0 | |
| 7 | 5 | |
| 8 | Extended therapy with Lu-177-PSMA-617 in patients with high tumor load metastatic castration-resistant prostate cancer | 0 |
| 9 | Radioligand Therapy with 177Lu-PSMA-617 in Patients with Diffuse Bone Marrow Involvement: Safety and Efficacy Results | 2 |
| 10 | 3 | |
| 11 | 9 | |
| 12 | 46 | |
| 13 | 11 | |
| 14 | 82 | |
| 15 | 16 | |
| 16 | 23 | |
| 17 | 13 | |
| 18 | 41 | |
| 19 | 17 | |
| 20 | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.